compound introduction
Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses . Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria In Vitro Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC 50 s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:IC50: 19.6 μM (SARS-CoV-2)
